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therapy during which a patient’s self-regulation capacity is ex-
traordinarily challenged. 
Accordingly, we investigated the association between pretreat-
ment CVT and residual symptoms after exposure therapy and 
dropout from exposure therapy in a sample of 228 patients with 
panic disorder and agoraphobia (PD/AG). These PD/AG patients 
underwent a standardized and manualized treatment focusing on 
exposure in vivo in a randomized controlled trial carried out in 
multiple centers [6, 7]. For the current research question, patients 
were grouped into those who were (1) fully recovered or (2) showed 
residual symptoms according to clinician ratings after completion 
of treatment, and (3) treatment dropouts. Clinician ratings were 
standardized using the Clinical Global Impression Scale (CGI) that 
measures the overall severity of a disorder with scores that range 
between 1 (no disorder) and 7 (among the most severely ill pa-
tients). The assessment of pretreatment CVT as indexed by heart 
rate variability (HRV) was based on electrocardiogram data col-
lected during a relaxation period of a highly standardized Behav-
ioral Avoidance Test (BAT [8]) prior to therapy. The root mean 
square of successive differences (RMSSD) and high-frequency 
(HF) HRV (frequency band: 0.15–0.40 Hz) were determined using 
HRV analysis (see online suppl. material for more information 
about participants, treatment, outcome assessment, HRV assess-
ment, and data analysis; for all online suppl. material, see www.
karger.com/doi/10.1159/000487599).
Thirty-nine patients (17.1%) dropped out from therapy prior 
to postassessment. In patients completing treatment, postassess-
ment CGI scores lower than 3 indicated no more clinically relevant 
symptoms (i.e., full recovery) in 28 patients (12.3%), and CGI 
scores of 3 or more indicated residual symptoms in 161 patients 
(70.6%). Neither the group with residual symptoms nor the treat-
ment dropout group differed from the fully recovered group with 
regard to baseline levels of symptom severity (see online suppl. 
Table S1). As shown in Figure 1, however, the groups differed with 
regard to pretreatment HRV. The group with residual symptoms 
had lower pretreatment HRV than the fully recovered group: 
RMSSD: t(187) = 2.27, p = 0.024; HF-HRV: t(187) = 2.35, p = 0.020. 
Likewise, the treatment dropout group had lower pretreatment 
HRV than the fully recovered group: RMSSD: t(65) = 2.69, p = 
0.009; HF-HRV: t(65) = 2.33, p = 0.023).
To predict residual symptoms, binary logistic regressions were 
conducted using either RMSSD or HF-HRV scores to indicate 
HRV together with sex and age as well as CGI scores as indicators 
of baseline symptom severity. Fully recovered patients served as a 
reference group. The Wald criterion indicated that only HRV 
made a significant contribution to predict residual symptoms: 
RMSSD: 4.27, p = 0.039; HF-HRV: 4.25, p = 0.039 (see online sup-
pl. Table S2 and text). The same setup for binary logistic regres-
sions was applied to predict treatment dropout as opposed to full 
recovery and, again, the Wald criterion indicated that only HRV 
made a significant contribution to predict treatment dropout: 
Exposure therapy is a well-established and effective treatment 
for pathological anxiety. However, high dropout and nonre-
sponder rates call for the investigation of individual differences 
that mediate treatment response [1]. Among physiological indi-
vidual differences, cardiac vagal tone (CVT) seems a promising 
candidate to predict treatment response: CVT has been linked to 
cognitive, affective, social, and health functioning levels [2] and 
low CTV has been found in a variety of anxiety disorders [3]. To 
test the association between CVT and treatment response, we fol-
lowed two lines of argument. First, low CVT has been associated 
with a deficit in extinction learning which is considered an under-
lying mechanism of exposure therapy [e.g., 4]. Given that patho-
logical anxiety is also associated with an extinction learning deficit 
[5], CVT may qualify as a factor moderating this association. That 
is, anxiety patients with low CVT may show less extinction during 
exposure therapy and, thus, may more likely show residual symp-
toms. Second, CVT has been linked to self-regulation capacity [2] 
and, thus, may impact the likelihood of dropout from exposure 
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RMSSD: 4.72, p = 0.030; HF-HRV: 3.40, p = 0.065 (see online 
suppl. Table S3 and text). 
These findings indicate that PD/AG patients with low pretreat-
ment CVT are more likely to show residual symptoms after com-
pleting exposure-focused therapy. Previous research showed that 
low CVT is associated with a deficit in safety learning during fear 
extinction training [e.g., 4]. Both CVT [9] and extinction learning 
[10] are mediated by inhibitory pathways from the prefrontal cor-
tex to brainstem regions mediated by the amygdala. According to 
the model of neurovisceral integration [9], this inhibitory cortico-
subcortical network enables the organism’s adaptation to chang-
ing environments (e.g., to the absence of an expected threat) by 
integrating autonomic, attentional, and affective systems. Thus, 
PD/AG patients with lower levels of prefrontal cortex activity as 
indexed by CVT may experience less effective fear extinction and, 
thus, may more likely show residual symptoms after completing 
exposure-focused therapy. 
In addition, low pretreatment CVT also predicted treatment 
dropout in the present study. Entering an exposure situation in 
which a patient confronts what they most fear (up to and including 
in some cases the fear of dying) and have long since avoided cer-
tainly demands high levels of self-regulation from PD/AG patients. 
Patients with particularly low pretreatment CVT may have lower 
levels of self-regulatory capacity and, therefore, more pronounced 
difficulties in entering and/or remaining in a feared situation. This 
assumption is further strengthened by the finding that pretreat-
ment CVT is particularly low in patients stating motivational rea-
sons for dropout, e.g., “too afraid to enter exposure situation” (see 
online suppl. Fig. S1 and text). Thus, PD/AG patients with low 
CVT may benefit from increased guidance by the therapist during 
exposure exercises [8]. Indeed, results from this clinical trial 
showed that patients who are accompanied by a therapist profit 
more from exposure therapy than those without guidance [7], es-
pecially if pronounced situational avoidance behavior has to be 
overcome during treatment [8]. In the case of CVT, such tailored 
treatments are feasible for the practitioner because CVT can be 
increased by different interventions such as meditation, exercise 
training, or biofeedback. In conclusion, PD/AG patients with low 
CVT may benefit from the implementation of such low-intensity 
interventions prior to undergoing exposure therapy.
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Fig. 1. Pretreatment levels of heart rate variability (HRV) in the 
fully recovered group, the group with residual symptoms, and the 
treatment dropout group. Bar charts represent means and stan-
dard errors of logarithmized values from the root mean square 
of successive differences (RMSSD; a) and high-frequency (HF)-
HRV (b).
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